ANDA 211075, held by Granules India. Fexofenadine Hydrochloride.
As of Nov 21, 2026, ANDA 211075 (Fexofenadine Hydrochloride Allergy), held by Granules India, was first approved by FDA on Oct 18, 2019, with 1 approved supplement and 0 published complete response letters.
Uses reduces hives and relieves itching due to hives (urticaria). This product will not prevent hives or an allergic skin reaction from occurring.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 18, 2019 | Original application | Approved | None posted |
| Fexofenadine Hydrochloride Allergy60MG · tablet;oral | Fexofenadine Hydrochloride | OTC |
| Fexofenadine Hydrochloride Allergy180MG · tablet;oral | Fexofenadine Hydrochloride | OTC |
| Jan 4, 2024 | Supplement 8Labeling · Standard review | Approved | None posted |
| Oct 18, 2019 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters